Angiographic Surrogates Gaining Importance For DES Trials – CDRH’s Boam

Surrogate angiographic endpoints are important to maintaining manageable enrollment numbers in drug-eluting stent clinical trials, according to FDA's lead interventional cardiology device reviewer